stereotaxis.com - STXS Company Value to Revenue Ratio

Public company logo of Stereotaxis (STXS)

Current EV/Sales dynamics for Stereotaxis, Inc. (STXS) demonstrate the impact of high system costs and the slow adoption of robotics in cardiology, where 3519.19 reflects the latest metric value. Profit growth is constrained by lengthy deal cycles with clinics that require strict cost controls. However, Stereotaxis, Inc. (STXS) is building a formidable barrier to entry for competitors through the Genesis ecosystem, which integrates software and hardware into a single comprehensive complex.

STXS Stereotaxis, Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

STXS (Stereotaxis Corp): analytical breakdowns and indicator data

Fundamental valuation:Stereotaxis, Inc. STXS
Mass-produced product of Stereotaxis Inc

Stereotaxis, Inc. (STXS) is developing robotic navigation through strategic alliances with cardiac clinics and catheter manufacturers. This synergy is reflected in the value of 3519.19, which combines market capitalization and net debt relative to annual turnover. The metric measures the real value of assets, excluding the impact of leverage on the valuation. The stability of this parameter confirms the business's resilience to market shocks. Analyzing the ratio of enterprise value to annual revenue allows for the timely identification of a shift in the global trend.

Competitor analysis for Stereotaxis, Inc.

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple AxoGen, Inc. AXGN|SI-BONE Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Orthofix Medical OFIX|Bioventus Global (BVS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume KIDS (OrthoPediatrics Inc.)|Enterprise Value-to-Revenue Ratio treace.com|Company Value to Revenue Strata Critical Medical Inc (SRTA)|EV/Sales Multiple CARL|RXST - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio clearpointneuro.com CLPT|STIM: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio